Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus neoadjuvant chemotherapy for conversion of unresectable esophageal squamous cell carcinoma
ChiCTR2600119169Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: R0 resection rate. Started Feb 2026; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600119169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119169.